

© d-maps.com

XI Corso Nazionale Società Italiana Banche degli Occhi

Imola, 1 Aprile 2017

**Overview sui controlli microbiologici europei:
aggiornamenti EEBA 2017.**

Dott.ssa P. Santoro
Banca delle Cornee della Regione Piemonte


XXIX. ANNUAL MEETING OF THE EUROPEAN EYE BANK ASSOCIATION

19 – 21 January 2017, Prague Marriott Hotel, Prague – Czech Republic



EUROPEAN
EYE BANK
ASSOCIATION

P R A G U E
January 19 - 21



PROGRAMME

ABSTRACTS

International Eye Bank of Prague
Organising Committee

Srobarova 1150/50 • 100 34 Prague 10 • Czech Republic • Fax: +420 267 311 835 • E-mail: EEBA2017@bppcz

EEBA 2017

XXIX. ANNUAL MEETING OF THE EUROPEAN EYE BANK ASSOCIATION



SATURDAY 21st JANUARY, 2017

08:30 - 09:30

EEBA Business Meeting / Bohemia II. room

09:30 - 10:00

Coffee Break and Poster Session

10:00 - 10:45

1st Morning session

Cornea Storage / Tissue Media

Chairman: Katerina Jirsova, Thibaud Garcin

10:00 - 10:10

30. Thibaud Garcin - Saint-Etienne, France (page 43)
Preclinical controlled study comparing long-term stored human corneas in an innovative bioreactor versus standard organ-culture

10:10 - 10:20

31. Jana D'Amato Tóthová - Monza, Italy (page 44)
Evaluation of donor corneas preserved in a new cold storage medium with antimycotic tablet

10:20 - 10:30

32. Ina Wilkemeyer - Berlin, Germany (page 45)
Organ Culture Preservation of Human Donor Corneas without Antibiotics

10:30 - 10:40

33. Laura Giurgola - Monza, Italy (page 46)
Validation of microbiological test of corneal preservation media according to "Method suitability test" of European Pharmacopoeia (chapter 2.6.1.)

10:40 - 10:45

Domenico Amato - Ponte San Nicolò, Italy
Company presentation: AlchiMIA S.r.l.
What is a medical device and how to develop it

EEBA 2016



EUROPEAN
EYE BANK
ASSOCIATION

Saturday, January 23

2nd Morning session

11:30 – 12:20

Microbiology & safety (Maier & Lauterbach)

11:30 – 11:40

T. Sorgenfrei, Hildesheim:
Relationship between conjunctival swabs and contamination in organ culture of corneas

11:40 – 11:50

Z. Skenderi, Berlin:
A New Approach for Sterility Testing of Corneal Organ Culture Medium

11:50 – 12:00

I. Wilkemeyer, Berlin:
Validation of Sterility Testing for Cornea Organ Culture Medium Containing Antibiotics using Blood Culture Bottles with Penicillinase as Additive

12:00 – 12:10

D'Amato Tóthová, Monza:
Development of a cold storage medium with lyophilized antimycotic

12:10 – 12:20

E. Martínez-Conesa, Barcelona:
Five years analysis of microbiological contamination in organ-cultured corneas in Barcelona Tissue Bank

12:20 – 13:00

Donor selection Workshop (Beele & Trias)

lecture no 31

Evaluation of donor corneas preserved in a new cold storage medium with antimycotic tablet

Title:

Pateri F.¹, Limongelli A.¹, Tomasiello D.¹, Giurgola L.², Gatto C.², D'Amato Tóthová J.², Mistò R.¹

Authors:

¹ Monza Eye Bank, San Gerardo Hospital, Monza (MB), Italy

Institution(s):

² Alchilife S.r.l., Ponte San Nicolò (PD), Italy

First author e-mail:

fpateri@asst-monza.it

Text:

Introduction
A new cold storage medium (ECS) with an effective antimycotic concentration, fast dissolving tablet was designed to prevent yeast contamination of donor corneas intended for transplantation.

lecture no 33

Validation of microbiological test of corneal preservation media according to "Method suitability test" of European Pharmacopoeia (chapter 2.6.1.)

Title:

Anna Limongelli¹, Francesca Pateri¹, Elisabetta Frigerio¹, Antonia Masin¹, Laura Giurgola², Jana D. Tothova², Raffaella Mistò¹

Authors:

¹ Eye Bank of Monza, San Gerardo Hospital, Monza, Italy

Institution(s):

² ALCHILIFE srl, Ponte San Nicolò, Italy

First author e-mail:

a.limongelli@asst-monza.it

Text:

Purpose
The aim of this study was to validate the microbiological test of corneal preservation media according to the "Method suitability test" (EP) using the HB&L (HB&L, Alifax) and BACTEC (Becton Dickinson) automatized systems.

Organ Culture Preservation of Human Donor Corneas without Antibiotics

Ina Wilkemeyer, Zemra Skenderi, Axel Pruß, Jan Schroeter

Cornea Bank Berlin, University Tissue Bank, Institute for Transfusion Medicine, Charité – Universitätsmedizin Berlin

inawilkemeyer@gmail.com

Purpose

Since antibiotics in the organ culture medium may inhibit the microbial growth in microbiological testing, and therefore, might lead to false negative results, we started to investigate the organ culture of human donor corneas without antibiotics.

Materials and Methods

62 human donor corneas not suitable for transplantation were organ-cultured for 39 hours, on average, with a standard medium (MEM with 2% FCS containing 130 µg/ml Streptomycin, 60 µg/ml Penicillin and 2,5 µg/ml Amphotericin B) at $32 \pm 1^\circ\text{C}$. This was followed by a preservation with MEM with 2% FCS without antibiotics for an average of 28 days at $32 \pm 1^\circ\text{C}$. The medium was changed 3 to 4 times, with an average interval of 9 days, and tested for microbiological contamination by incubating 10 ml of the medium in aerobic and anaerobic blood culture bottles (Bactec automated blood culture system with standard vials, BD). At the end of the organ culture period, the corneas were transferred into Thioglycolate broth for microbiological testing for 14 days at $35 \pm 1^\circ\text{C}$.

Results

3 corneas showed a clear contamination of the organ culture medium after 4-5 days of cultivation, which was confirmed by microbiological testing. All other 59 corneas showed no signs of microbial contamination, and all microbiological tests remained negative.

Conclusion

With a rather low rate of microbial contamination of 4,8% in this study, a continuous antibiotic treatment during organ culture may not be necessary. Further investigation is necessary to determine if this study found addition contaminations when are hidden in media containing antibiotics, or if preservation without antibiotics leads to a higher contamination rate in general.

Technical guidelines 02/2015

1. A minimum storage period is mandatory to allow for proper microbiological testing thus minimizing the risk of contamination
2. The efficacy of this quarantine period and the microbiological testing method should be evaluated and validated due to antibiotics within the storage media.
3. Microbiological testing of media samples is mandatory, sole visual inspection of the medium for a change in colour or transparency is not acceptable.

Technical guidelines 02/2017

An inspection of the endothelium is mandatory and the cell loss during storage must be taken into account, except for tissue designated for emergency or anterior lamellar grafting. Due to the short time of storage, it is not possible to wait for the final result of sensitive microbiological testing of the culture medium using traditional microbiological testing (e.g. blood-culture bottles) but there are alternative testing-methods available. However, sampling of the culture medium one day after the start of the storage period, or just before delivery for clinical use is recommended. The efficacy of the used microbiological testing method should be evaluated and validated due to the presence of antibiotics within the storage media. The treating physician/receiving transplanting centre should be informed as quickly as possible in the event of a 'late' positive result. Instruction for surgery-use with recommendation of microbiological testing of corneal storage medium and/or remaining scleral rim at time of surgery should be added.(see 3.7)

- Storage of the corneoscleral button by organ/tissue culture: It is recommended to keep the storage time as short as possible with a maximum of 34 days for selected surgery cases. Inspection of the endothelium is mandatory and should be preferred in any case at the end of the storage period except for tissue designated for emergency or anterior lamellar grafting.

A minimum storage period is mandatory to allow for proper microbiological testing thus minimizing the risk of contamination. The time period required to perform microbiological tests of the storage medium is at the discretion of the Responsible Person. The efficacy of this quarantine period and the microbiological testing method should be evaluated and validated considering the effectiveness of antibiotics within the storage media.

Microbiological testing of media samples is mandatory, sole visual inspection of the medium for a change in colour or transparency is not acceptable. Medium change during storage using aseptic procedures is at the discretion of the Responsible Person and the indications of the manufacturer - taking into consideration that corneal endothelium might be stressed if tissue is to be transferred into other solutions/media.

Technical guidelines 02/2017

3.7 Clinical Use

A preservation and expiry date for the cornea shall be indicated. If medium changes are performed, these dates should be indicated as well as the date and time of transfer to transport medium.

Microbiological testing of medium and/or remaining scleral rim postoperatively is highly recommended, especially due to the fact that tissue is not considered to be sterile (and storage medium is not bactericidal).

Rischio di endoftalmite post trapianto

- Studio delle banche degli occhi tedesche condotto nel 2007:
rischio di 0,035%
- Dati di letteratura:
Birnbaum e Reinhard (2006) e Taban et al. (2005):
rischio da 0,1% a 0,38%.

Pels (2008) {
rischio da 0 a 0,1% per cornee di coltura
rischio da 0,2 a 1,3% per cornee a freddo

Controlli microbiologici nelle Banche degli Occhi Europee

Il rischio microbiologico connesso al trapianto di cornee conservate a caldo si riduce con:

- Disinfezione prima del prelievo
- Presenza di antibiotici e/o antifungini nei liquidi di conservazione
- Presenza di indicatori di pH nei liquidi di conservazione
- Controlli microbiologici durante la quarantena
- Controllo del liquido di trasporto

Test microbiologici

Risposte da 57 banche EEBA



Eye Bank of Munich


1. E-swabs from conjunctiva/anterior chamber after decontamination (at time of retrieval)
2. Sterility testing of medias during storage (hypothermic and organ cultured tissues)
3. Swabs/sterility control of remaining scleral rim/media (AFTER transplantation)
4. Inoculation onto TSB/Thio Sab broth for all testing samples (400 µl/14 days)

- *Staphylococcus epidermidis*
- *Enterococcus faecalis*
- Rare *Candida*

Controlli microbiologici nelle Banche degli Occhi Europee

Il rischio microbiologico connesso al trapianto di cornee conservate a caldo si riduce con:

- Disinfezione prima del prelievo
- **Presenza di antibiotici e/o antifungini nei liquidi di conservazione**
- Presenza di indicatori di pH nei liquidi di conservazione
- Controlli microbiologici durante la quarantena
- Controllo del liquido di trasporto



1. Penicillina G/Streptomicina/Amfotericina B (Alchimia)
2. - Penicillina/Streptomicina/Amfotericina (MEM FBS 2 %)
- Amukina/Tazocin/Nistatina (MEM FBS)
3. Penicillina/Streptomicina/Amfotericina B (Eagle's MEM FBS 2%)
4. Biklin/Piperacillina/Fungizone (MEM FBS)
5. Penicillina/Streptomicina (Eurobio Cornea Prep, Max e Jet FBS)
6. Penicillina/Streptomicina (Eurobio Cornea Prep, Max e Jet)
7. Penicillina/Streptomicina/Amfotericina B (EMEM, MEM, Biochrom Culture Medium I, II, DMEM, Cornea Max Eurobio, Alchimia)
8. Penicillina/Streptomicina/Amfotericina (Alchimia, MEM FBS)
9. - Penicillina/Streptomicina/Amfotericina B (MEM FBS)
- Penicillina/Streptomicina (Cornea Max Eurobio)
10. Garamicina/Vancomicina/Amfotericina B (MEM)
11. Penicillina/Streptomicina/Amfotericina B (Alchimia)
12. - Biklin, Piperacillina/Tazobactam,Fungizone (MEM FBS 8%)
- Biklin,Piperacillina/Tazobactam, Nistatina (MEM FBS 8%)
13. Penicillina/Streptomicina/Amfotericina B (Eurobio e Stem alpha)
14. Penicillina/Streptomicina/Amfotericina B (Eagle's MEM FBS 2%)

Antibiotici e antifungini presenti nei terreni di conservazione utilizzati in Europa

Antibiotici	Antifungini
Penicillina - Streptomicina	Amfotericina
Penicillina - Streptomicina	
Amukina – Tazocin*	Nistatina
Amikacina – Tazocin*	Nistatina
Amikacina – Tazocin*	Fungizone**
Garamicina** - Vancomicina	Amfotericina

*Amikacina – Tazocin = Biklin + Piperacillina/Tazobactam

**Amfotericina

***Gentamicina

Quantità di antibiotici e antifungini presenti nei terreni di conservazione utilizzati in Europa

Antibiotici	Quantità
Penicillina	100 u 1.000 u 10.000 u 100.000 u
Streptomicina	0,1 mg 1 mg 10 mg
Biklina (Amukina)	100 µg 200 µg
Tazocin (piperacillina+tazobactam)	0,5 mg 0,2 mg 2 mg
Garamicina (gentamicina)	50 µg
Vancomicina	100 µg

Antifungini	Quantità
Amfotericina (Fungizone)	0,25 µg 0,50 µg 2,50 µg 25 µg 250 µg 2500 µg 5 mg
Nistatina	

Siero Bovino Fetale	Quantità
FBS	2 %
FBS	8 %

Percentuale di Cornee eliminate per controlli microbiologici positivi in EEBA

2014	3,1 %
2015	2,6 %

Percentuale di Cornee eliminate per controlli microbiologici positivi in Torino

2014	3,5 %
2015	2,3 %
2016	1,7 %

Tipi di microrganismo rilevati presso la Banca di Torino



2014		2015		2016	
GRAM -	20 %	GRAM -	20 %	GRAM -	37 %
GRAM +	30 %	GRAM +	30 %	GRAM +	53 %
FUNGHI *	50 %	FUNGHI **	50 %	FUNGHI	10 %

* 33 % contaminazioni rilevate sul terreno di trasporto


** 40 % sul terreno di trasporto

Alcune considerazioni.....

CORSO SIBO 2016
Palazzo delle Arti di Napoli – 23 Aprile 2016



Cause di decesso dei donatori (Banca degli Occhi di Torino 2007 - 2015)



	2012		2013		2014		2015		2016	
Batteri	94 %	Batteri	90 %	Batteri	50 %	Batteri	50 %	Batteri	90 %	
Funghi	6 %	Funghi	10 %	Funghi	50 %	Funghi	50 %	Funghi	10 %	

Classificazione secondo il TIPO D'AZIONE

L'azione dell'antibiotico può essere:

Batteriostatica:

l'antibiotico blocca la riproduzione dei batteri

Battericida:

l'antibiotico determina la morte dei batteri. Si definisce battericida l'antibiotico il quale dopo 24 h di contatto "in vitro" determina una sopravvivenza uguale o inferiore allo 0,01%.


AMINOGLICOSIDI



La **streptomicina** è un [antibiotico](#) batteriostatico a dosi terapeutiche, a dosi superiori diventa battericida, il primo ad essere scoperto di una famiglia chiamata [amminoglicosidi](#), uno dei primi rimedi contro la [tubercolosi](#).

Principalmente attivi contro batteri aerobici Gram - come *Pseudomonas*, *Acinetobacter* ed *Enterobatteri*.

Inefficaci contro gli anaerobi.



La piperacillina appartiene alla classe dei β -lattamici, del gruppo delle penicilline (penicillina semisintetica, dotata di attività battericida). Normalmente associata ad un inibitore della β -lattamasi, in particolare nella combinazione piperacillina/tazobactam. Il tazobactam può prevenire la [resistenza](#) di alcuni batteri verso la piperacillina. Ciò significa che quando la piperacillina e il tazobactam vengono somministrati insieme, più tipi di batteri vengono uccisi.

Spettro batterico ampio, attiva verso batteri aerobici Gram + (*Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Enterococcus faecalis*) e batteri Gram - (*Pseudomonas aeruginosa*, *Serratia marcescens*, *Enterobacteriaceae*, *Klebsiella pneumoniae*, *E. coli*) e diversi anaerobi (tra cui *Bacteroides fragilis*).

GARAMICINA —————> **GENTAMICINA**

GLICOPEPTIDI



VANCOMICINA

Effetto battericida, inefficace contro i batteri Gram -, ad eccezione dei *Flavobacterium*.

La somministrazione contemporanea di vancomicina e di gentamicina e streptomina potenzia l'azione nei confronti di *Enterococcus faecium* ed *Enterococcus faecalis*; attivo contro gli *Stafilo* produttori di *b*-lattamasi e resistenti alla meticillina, alla nafcillina e alla oxacillina.

Gentamicina e kanamicina sono marginalmente efficaci contro i micoplasmi, contro i quali si preferisce utilizzare TIAMULIN, MINOCICLINA e **VANCOMICINA**.

ANTIMICOTICI

AMFOTERICINA B
(0,2 µg/mL – 2 µg/mL)

NISTATINA
(100 U/mL e 250 U/mL)

L'amfotericina è un fungicida e fungistatico, a seconda del microrganismo e della concentrazione del [farmaco](#). È efficace contro un'ampia varietà di funghi, come: [candida albicans](#), *coccidioides*, [aspergillus](#) e *blastomices*

Grazie !!!